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Statement of the Problem 
 
As of December 2001, the total number of people living with HIV/AIDS (PLHA) is estimated at 40 
million. Most of these people live in the developing world (UNAIDS and WHO 2001). While there 
are indications that the incidence of HIV infection has been declining in some countries, in many 
others incidence rates remain high or are increasing. Consequently, the prevalence of HIV infection 
is likely to continue to rise. In the absence of treatment, most people infected with HIV will 
eventually develop an HIV-related disease and succumb to the consequences of the infection. 
 
Advances in the development and availability of antiretroviral drugs have led to a paradigm shift in 
most of the industrialized world, where highly active antiretroviral therapy (HAART) has resulted 
in a significant reduction in the prevalence of AIDS-related morbidity and mortality. AIDS has, in 
the eyes of many, become a manageable chronic disease. 
 
In most of the developing world, however, the focus of national programs and international support 
continues to be on prevention, care, and support in the absence of antiretroviral treatment. Notable 
exceptions are Brazil, Thailand, Senegal, and Botswana, which have made antiretrovirals (ARVs) 
available to people with AIDS through public sector efforts. Other exceptions include countries 
that have initiated pilot antiretroviral treatment programs, including Côte d’Ivoire, Uganda, Chile, 
and Vietnam. 
 
While the moral imperative to provide the best possible treatment for people with AIDS-related 
disease is widely recognized, national governments and donors have been reluctant to enter into 
this endeavor. They cite numerous concerns, ranging from the cost of ARVs to the capacity of 
health care delivery systems in the developing world to the ability of patients to adhere to lifelong 
treatment regimens. However, the cost of antiretroviral drugs continues to decrease and ARVs are 
now available through private channels in almost all countries in the world. The above-mentioned 
concerns remain, however, and both ministries of health and the international donor community 
need guidance on how to develop and implement appropriate and effective HIV/AIDS treatment 
programs.  
 
A successful treatment program is the result of the synergy between a large number of components. 
In an ideal situation, appropriate drugs with few or no side effects are accessible and affordable to 
those who need them. Those who need the drugs seek and adhere to treatment freely and without 
fear of stigmatization or discrimination, and health care workers monitor treatment and adapt 
regimens to suit individual patients. While impressive progress has been made in many of these 
areas of HIV/AIDS treatment, numerous challenges and questions remain.   
 
To explore and prioritize operations research questions about access to treatment for HIV/AIDS, 
the Horizons Program convened a two-day meeting of international researchers and program 
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managers in Washington, D.C., on 12–13 June 2001. The meeting focused specifically on the 
following key questions: 
 
• What are the operational issues encountered in providing HIV/AIDS treatment in different 
settings? 
• What are the most important operational challenges and testable solutions in providing 
access to treatment? 
• How do these challenges and solutions differ by region and subpopulation? 
• What are some of the important research design and measurement issues that need to be 
considered in addressing key issues concerning access to treatment? 
 
This report presents the findings and recommendations discussed at the meeting. The report begins 
with a summary review of aspects of antiretroviral programs and then discusses the following 
critical elements of treatment programs:  
 
• Health systems and service delivery 
• Biomedical issues 
• Behavior of health care workers and clients 
• Stigma, discrimination, and ethical issues 
• Community involvement 
• Cost and cost recovery 
• Policy  
• Programmatic issues 
 
The discussions at the two-day meeting covered a wide range of topics at times, but an effort has 
been made in this report to concentrate on the important operational issues concerning access to 
treatment that need to be addressed through research. It is recognized that treatment for HIV/AIDS 
is more than antiretroviral therapy; rather, it includes treatment of opportunistic infections and 
palliative and end-of-life care. While the discussion focused on treatment with ARVs, many of the 
issues raised and the research questions identified also pertain to treatment of opportunistic 
infections and the provision of palliative and end-of-life care. 
 
Finally, the participants at the meeting brought to the table a rich and diverse experience with 
HIV/AIDS treatment, care, support, and prevention. Most participants made short presentations 
that provided the basis for in-depth discussion. For the purposes of this report it did not seem 
desirable to summarize every presentation, but rather to ensure that the substance of the 
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Antiretroviral Therapy Programs: Issues and Considerations 
 
The availability of HAART in the industrialized world has greatly reduced AIDS-related mortality, 
while the number of PLHA in many countries continues to increase. Thus, in the United States, the 
number of PLHA increased from 174,244 in 1993 to 317,368 in 1999, while mortality associated 
with AIDS decreased from 45,494 to 16,767 in that same period (CDC 2000). Initially the cost of 
ARVs was perceived as an insurmountable obstacle to wide-scale provision of antiretroviral 
therapy in the developing world. However, recently these costs have come down to levels that are 
affordable to at least some national health systems outside of the industrialized world and to some 
individuals in even the poorest countries. For instance, the cost of triple antiretroviral therapy has 
decreased from US$800–1,100 per month to US$100–300 per month. This still represents an 
enormous cost, however, especially in relatively poor countries with a high prevalence of HIV 
infection. Nonetheless, the cost of not providing antiretroviral therapy is also enormous in terms of 
morbidity and mortality, declining agricultural and industrial productivity, increased numbers of 
orphans, and great economic hardships for affected families.  
 
 
Comprehensive prevention, care, and support 
 
It is important to realize that antiretroviral therapy is only one component of a comprehensive 
HIV/AIDS program that also includes prevention and other care and support activities. Figure 1 
provides a schematic overview of a comprehensive HIV/AIDS care program. These components 
not only complement but also mutually reinforce each other. Treatment programs are developed 
and implemented in the context of existing health care delivery systems. Other components of 
HIV/AIDS treatment and care include counseling and testing; the control and management of 
sexually transmitted infections (STIs); prophylaxis for certain opportunistic infections (OIs), such 
as tuberculosis (TB) and pneumocystis carinii pneumonia (PCP); treatment for OIs; and palliative 
care. Many PLHA will not initially qualify for antiretroviral therapy, and not all who receive 
antiretroviral therapy benefit equally.  Studies in the industrialized world demonstrate highly 
variable rates of long-term suppression of viral particles in the peripheral blood, ranging from 32 
percent in patients who received antiretrovirals before initiating HAART to 37–82 percent in 
patients who had never received antiretroviral treatment (Lucas et al. 1999; Servais et al. 2000; 
Yamashita et al. 2001). Lack of long-term benefit is strongly associated with less-than-perfect 
adherence, treatment discontinuation, and viral resistance, and possibly with the number of CD4 
cells present at treatment initiation. A significant number of people on HAART discontinue 
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Although antiretroviral treatment is a rapidly evolving field and experience with such programs is 
relatively limited, it is nevertheless clear that as a component of comprehensive care and support 
programs ARVs can reduce HIV-related morbidity and mortality and improve the quality of life of 
people living with HIV/AIDS. Antiretroviral treatment might also contribute to reduced 
transmission of HIV by lowering the viral load and thus reducing the infectiousness of PLHA. The 
availability of antiretroviral therapy is likely to provide an incentive to seek voluntary counseling 
and testing (VCT) and to learn about one’s serostatus, which in turn might contribute to safer 
sexual behavior.   
 
Despite the many problems of antiretroviral treatment programs, they have the potential to 
significantly complement and enhance comprehensive HIV care and support programs, 
and, possibly, other health care programs.  (Eric van Praag, FHI/IMPACT) 
 
 
Antiretroviral drugs, resistance, and treatment monitoring 
 
Currently, there are three classes of drugs that block replication of HIV in the cell: 
 
• Nucleoside reverse transcriptase inhibitors (NRTI)–such as zidovudine (AZT), 3TC, ddI, 
d4T, ddC, and Combivir (a combined preparation with AZT and 3TC) 
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• Non-nucleoside reverse transcriptase inhibitors (NNRTI)–such as nevirapine, delavirdine, 
and efavirenz 
• Protease inhibitors (PI)–such as ritonavir, indinavir, nelfinavir, and saquinavir 
 
Each class of drugs has its own side effects, many of which are potentially very serious. Common 
side effects are headache, nausea, vomiting, fatigue, and diarrhea. Some people have problems 
eating or sleeping. Some other complications associated with specific classes of drugs include 
lipodystrophy (fat redistribution) syndrome, hepatomegaly (liver enlargement), pancreatitis, and 
anemia. It is important that both health care workers and people taking antiretroviral therapy are 
well aware of these side effects. 
 
A combination of drugs from different classes is required for a sustained reduction of the viral load 
in the peripheral blood, because resistance to a single drug usually develops rapidly. At the very 
least, treatment regimens should provide for double therapy, but optimal regimens consist of a 
combination of three drugs. Current recommendations for triple therapy are two NRTIs and one PI 
or two NRTIs and one NNRTI. The only exception to these recommendations is related to the 
prevention of mother to child transmission (MTCT), for which treatment of mother and child with 
a single drug has been shown to reduce significantly the incidence of HIV infection in the newborn 
baby. Treatment regimens are becoming easier to follow by combining different drugs in one pill 
or capsule and by developing formulations that require less frequent dosages. Still, some drugs 
require refrigeration for storage, and there is no single ideal combination of drugs. For optimal 
patient management, careful monitoring of the clinical response to a treatment regimen is needed 
so that treatment can be adapted to suit the clinical and immunological response as well as the 
needs of the individual patient.  
 
The development of HIV drug–resistant strains is a concern, especially when treatment is 
interrupted because of irregular adherence to treatment. Irregular adherence may be due to 
interruptions in the supply of drugs, problems with access to services, serious side effects, 
intermittent ability to pay for the drugs, or a patient’s increased sense of wellbeing. The fact that 
currently available antiretroviral therapy needs to be taken lifelong might also contribute to 
adherence problems. Resistant strains not only are a problem in the management of individual 
patients, but also could theoretically limit the usefulness of one or more classes of antiretroviral 
drugs at the community level. 
 
An additional complication is that many ARVs interact with other drugs that are commonly 
prescribed in developing countries, increasing the toxicity of some drugs and reducing the efficacy 
of others. This is the case, for instance, with rifampicin, commonly used for the treatment of 
tuberculosis, which reduces the efficacy of amprenavir, saquinavir, indinavir, and nelfinavir. It is 
important that physicians prescribing and monitoring antiretroviral therapy have a good 
understanding of these issues.  
 
Drug therapy for HIV/AIDS is rapidly evolving, and it is likely that treatment recommendations 
will continue to change as new drugs and new formulations become available. Treatment programs 




The impact of HAART is usually measured through assessments of the CD4 count and of the viral 
load in the peripheral blood. The CD4 count (the number of T-lymphocytes with a CD4 receptor) is 
a measure of the degree to which HIV compromises the immune system, while the viral load 
measures the number of circulating viral particles. The CD4 count is also used as a criterion for the 
initiation of treatment; persons whose CD4 count falls below a certain threshold are considered 
eligible for treatment with ARVs. These tests are expensive, however, costing roughly $100 per 
viral load test and $30 per CD4 test, and they demand highly qualified and well-trained laboratory 
staff, well-equipped laboratories, and high levels of quality control.  
 
 
Antiretroviral drugs and the health care system 
 
Implementing an antiretroviral therapy program places an additional strain on a health care system, 
in terms of its logistics, the providers, and the laboratory support system. Providers in the public 
sector as well as in the private sector, where antiretroviral drugs are generally more widely 
available, need to be trained and prepared to provide continuing clinical follow-up. Access to high-
quality care may be further compromised because of generally high levels of attrition among 
physicians and nursing staff resulting from HIV infection (of themselves or their families), low 
wages, burnout, and lack of motivation. A consistent supply of antiretroviral drugs must be 
available in order to avoid arbitrary treatment interruptions, and there should be sufficient 
laboratory capacity to do the initial testing, to assess a person’s HIV status, and to monitor CD4 
counts and viral loads. An intensive clinical and laboratory monitoring and information system also 
needs to be implemented. 
 
Although drug costs have dropped recently, the cost of antiretroviral drugs still remains 
considerable for most individuals and treatment programs. Added to the cost of drugs are the cost 
and effort required to strengthen and maintain the capacity of health care systems to deliver 
appropriate treatment programs. An HIV/AIDS treatment program could lead to new partnerships 
in health care delivery, for example, between the public and private sector, and to the strengthening 
of the overall health care system. However, it could also result in situations in which antiretroviral 
therapy programs are in competition for resources with other health care programs, and in which an 
emphasis on HIV/AIDS treatment leads to a deterioration of other programs, including HIV 
prevention efforts.  
 
 
Behavior, stigma, and discrimination 
 
Persons taking antiretroviral therapy may see less need to adopt or maintain safe behaviors because 
they mistakenly believe the treatment is curing them or that the virus is sufficiently suppressed to 
render them noninfectious. Similarly, the perception of ARVs as a cure for AIDS may also 
undermine behavior change programs and result in fewer people adopting or maintaining safe 
behaviors. A recent increase in high-risk behaviors among men who have sex with men in the 
United States has been associated with the availability of HAART (Remien 1998; Scheer 2001). 
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There are indications that with the widespread availability of HAART and the perception of AIDS 
as a manageable, chronic condition, levels of stigma and discrimination in the industrialized world 
may have decreased. However, in many parts of the industrialized world and in most of the 
developing world, PLHA are still subject to considerable stigmatization and discrimination. While 
increased availability of ARVs in the developing world might reduce stigma and discrimination, 
communities and PLHA also need to be involved in HIV/AIDS treatment programs to achieve this 
goal. It is likely that increased availability of ARVs will result in increased demands for voluntary 
counseling and testing and that antiretroviral therapy will result in increased disclosure, either 
voluntary or involuntary. Community and PLHA involvement could contribute significantly to 
reducing stigmatization while providing a supportive environment for all PLHA. Such a supportive 
environment could also play an important role in adherence to treatment recommendations. 
However, the current levels of actual or perceived stigma may still prevent people from seeking 
VCT and from accessing ARV programs, especially those provided by employers. 
 
 
Access and equity 
 
Not all people living with HIV need antiretroviral therapy. Whether a decision to treat is based on 
the CD4 count, viral loads, evidence of HIV-related disease, or a combination of these factors, it is 
likely that initially only a relatively small proportion of all those who are HIV-positive would 
qualify for antiretroviral therapy. Moreover, a patient’s readiness to start treatment needs to be 
taken into account. This requires a thorough understanding of the need to adhere to a relatively 
complex treatment that is to be taken lifelong. The number of patients eligible to start a treatment 
regimen is still substantial, with estimates on the order of 10–15 percent of those who are HIV-
positive or 3–5 million people worldwide. Over time, as more HIV-positive individuals progress to 
HIV-related disease and fewer people die of AIDS, this number could rise considerably. In many 
cases the cost of treatment and differences in the capacity of health care systems within countries 
will result in unequal access to treatment. Issues of equity will need to be addressed, although it is 
not possible to wait until a perfect system is in place before beginning treatment programs. The 
effect of insufficient VCT services, inadequate health care–seeking behavior, and the lack of easily 





Figure 2   Estimated proportion of HIV-infected people benefiting from effective use 
of ARV drugs: A theoretical model  
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Equity in access to treatment is especially important if the overriding goal of an HIV/AIDS 
treatment program is to achieve a therapeutic effect for all infected persons. Nonetheless, an 
argument can be made for the public health benefits of antiretroviral therapy directed at selected 
groups of people such as health care providers, teachers, uniformed services, truck drivers, and sex 
workers. Another group that could be considered are women who are found to be HIV-positive in 
MTCT programs and who play a crucial role as caretakers in the family. Such benefits include not 
only a reduction in morbidity and mortality associated with HIV/AIDS at the individual level, but 
also a potential reduction in transmission of HIV infection by HIV-positive individuals on 
antiretroviral therapy, as reductions in viral load are associated with reduced risk of transmission 
(Gray 2001). In the case of mothers, the benefits would include improved survival and 
development opportunities for her children and a reduction in the number of orphans. Pursuing the 
public health prevention benefits associated with antiretroviral therapy suggests that programs 
might focus initially on high-risk individuals or those with multiple partners and that these 
programs might start treatment early. Whether the focus of a treatment program is on all infected 
individuals or selected high-risk groups, an important question for program managers and 
policymakers is one of coverage. Critical decisions have to be made about which segments and 
what proportion of the population are to be covered by the treatment program.  
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Critical Aspects of Treatment Programs 
 
 
Health Systems and Service Delivery 
 
Human and institutional capacity  
 
Health care systems and their resource base differ from country to country and even within 
countries. The not-for-profit and private sectors play an important role in providing curative care 
for many people in the world. In fact, in most countries ARVs were available through the private 
sector before public sector programs were developed. Thus, a first step in the development of an 
HIV/AIDS treatment program is a situation analysis of the available services, capabilities, and 
capacity of the existing system. Particular attention should be paid to the training needs of health 
care personnel in the public and private sector, to the quality and location of laboratory services, 
and to the existing infrastructure for drug procurement and distribution.  As was pointed out earlier, 
the care and treatment needs of PLHA are not met by ARVs alone. Services for VCT need to be 
available; tuberculosis and other OIs need to be diagnosed and treated; prophylaxis for some OIs 
can be provided; and palliative and end-of-life care is required for many infected persons. The 
majority of people who are HIV-positive will in fact be asymptomatic; therefore, once they know 
their HIV status, they will initially need psychosocial support the most.  
 
A crucial element of a health care system is its staff. The initial situation analysis should pay 
attention not only to their levels of knowledge, but also to their motivation and commitment and to 
their attitudes toward people living with HIV/AIDS. Frequently, health care workers in the 
developing world are overworked and underpaid. They lack supplies, support, and supervision; 
they suffer from low morale and poor motivation; and they might fear occupational exposure to 
HIV infection. Care for PLHA is often seen as a waste of resources, because those patients are 
expected to die anyway. In addition, in many places stigma and discrimination lead to a rejection of 
HIV-positive individuals. Therefore, approaches to improve the capacity of health care systems to 
provide treatment, care, and support should focus not only on building skills and increasing 
knowledge, but also on improving the motivation and morale of staff and on strengthening health 
care systems.   
 
Health care systems in many countries suffer from a general lack of resources that leads to 
situations in which even essential drugs are often not available, supplies and equipment such as 
protective gloves are lacking, and even the presence of running water and electricity cannot be 
taken for granted. In turn, such health systems often function against a larger background of 
developmental and economic problems, characterized by corruption, internal displacement, civil 
strife, poor sanitation and water supply, unemployment, and internal and external migration. Or, as 
one participant put it: “We need better African economies.”  
 
The experience with large-scale antiretroviral therapy programs in Brazil and Thailand underscores 
the importance of capacity building within the health care delivery system. In Thailand, for 
instance, initially only a relatively small proportion of eligible persons received treatment, resulting 
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in only a small reduction in the national burden of HIV-related disease. Moreover, health care 
workers were not able to follow up on 70 percent of the patients because of a lack of infrastructure. 
Constraints to increasing coverage of the treatment program were identified as a lack of counseling 
capability, lack of health care personnel trained in ARV therapy, and a lack of clinical facilities 
with the capacity to monitor persons on treatment. To increase coverage of the program, qualified 























Making ARVs Accessible 
 
In Brazil, a network of facilities accredited for the provision of ARVs has been developed, 
where staff have been trained in both patient care and the interactions between ARVs and 
other drugs. Currently, 362 hospitals have been accredited to provide HIV/AIDS care. In 
addition to these facilities, outpatient and ambulatory care is provided through specialized care 
services at 148 facilities, 69 day hospitals, and 52 therapeutic home care initiatives. 
Laboratory capacity to conduct CD4 testing (70 laboratories) and viral load assessments (63 
laboratories) has also been developed.  
 
The UNAIDS-supported pilot program for the provision of ARVs in four countries (Vietnam, 
Uganda, Cote d’Ivoire, and Chile) started with developing human resources to support the 
programs, while making optimal use of existing services.   
 
In Uganda three centers for ARV treatment were operational in 1999; this is now being 
expanded to more than ten centers, which are expected to be qualified in 2001. In addition, 
planning is under way for three regional centers to provide services at the district level. 
 
 
While there is no doubt that training both public and private sector health care providers in 
HIV/AIDS care is needed, there is also an urgent need to evaluate the effect of quality-of-care 
training on health service use and the impact of such training on health. Guidance and training 
materials have been produced by WHO, UNAIDS, and other organizations (see References for a 
selection of materials for further reading).  
 
 
Interaction between HIV/AIDS care and other programs  
 
Countries in the developing world are typically faced with a range of health problems. While 
HIV/AIDS may have become one of the leading causes of morbidity and mortality in many 
countries, other infectious and noninfectious diseases remain important. There is a risk that the 
increased focus on antiretroviral therapy programs will be at the expense of established health care 
programs, many of which are already in need of additional funding and strengthening.  
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Within HIV/AIDS programs the allocation of resources needs to be carefully assessed. As was 
pointed out earlier, the provision of relatively expensive antiretroviral therapy is only one 
component of a comprehensive care program. It is by no means clear what the relative gains in 
quality-of-life and survival benefits are for those in ARV programs versus the benefits derived 
from less expensive prophylaxis and management programs for opportunistic infections. The 
UNAIDS pilot program for the provision of ARV was not able to document survival benefits or to 
demonstrate a reduction in the incidence of OIs and TB, possibly because many patients sought 
treatment very late in the course of their illness. Data from Brazil suggest that at least in the short 
term there is a reduction in mortality associated with the provision of HAART (Eyer-Silva 1998) 
and a reduction in the incidence of opportunistic infections. In Brazil, AIDS-related mortality 
dropped by 50 percent from 12.2/100,000 population in 1995 to 6.3/100,000 in 1999, while the 
incidence of various OIs decreased by 60-80 percent (Ministry of Health of Brazil 2001). There is 
an urgent need in the developing world to evaluate both ARV treatment programs and programs for 
the management of OIs for their impact on morbidity and mortality.  
 
 An excessive focus on antiretroviral therapy is an impediment to establishing a 
comprehensive care agenda, and an obstacle to decentralization. (Jos Perriens, UNAIDS) 
 
While some people argue that expensive ARV programs will weaken other health programs, it has 
been postulated that just the opposite could happen. The current attention to improving the systems 
for providing VCT and care for people with HIV/AIDS might also have a “ripple effect” of 
strengthening other health care systems. For instance, in Brazil, programs to increase access to 
antiretroviral therapy have increased local capacities for research, training, distribution of essential 
drugs, and management of complex information systems, and have led to better-integrated alliances 
between government, NGOs, and the community. Health planners need to balance an approach that 
calls for designing and implementing new systems to provide HIV/AIDS services and an approach 
that aims at improving and building on existing programs for providing these services. Operations 
research needs to determine the effect of each of these approaches.  
 
Within HIV/AIDS programs there is a similar need to balance care and prevention. The cost and 
effort required to deliver high-quality care and treatment may divert resources from ongoing 
prevention programs. It is therefore important to assess how strengthened HIV treatment programs 
will affect prevention programs. 
 
Finally, many PLHA will be need palliative and end-of-life care. This will be the case for those 
who do not receive antiretroviral treatment, those who stop treatment, and those in whom the virus 
has become resistant to the available antiretroviral drugs. Little is known about how to best provide 
palliative and end-of-life care and the needs of professional and lay caregivers to provide such care. 
 
 
Service delivery models  
 
A range of different service delivery models is being proposed, and operations research is needed 
to help evaluate the various approaches. The shortcomings of many health delivery systems in the 
developing world and the urgent need to address the care and support needs of ever-increasing 
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numbers of people who have HIV-related diseases may seem to suggest a vertical approach to HIV 
treatment programs. It might be easier to ensure drug logistics, prevent pilferage and misuse of 
antiretrovirals, and train and supervise dedicated staff in a vertical program. However, the large 
number of people who need care and support, the many facets of a comprehensive HIV care 
program, the complexities of a treatment delivery and monitoring system, and the imperative to 
implement programs that are sustainable suggest that an integrated approach might be more 
successful. An integrated approach will in many cases require a concerted effort to strengthen the 
health care system beyond the narrowly defined needs of an antiretroviral treatment program.  
  
An important component of a treatment program is laboratory support. Current approaches to 
identifying individuals eligible for treatment with ARVs and to monitoring patients on treatment 
rely on CD4 and viral load tests. These tests are expensive, at US$30 and $100 per test, 
respectively, and require a sophisticated laboratory infrastructure with good quality control. An 
urgent need exists to evaluate alternative methods of patient follow-up that rely on fewer or less 
frequent laboratory tests and that might be more appropriate for many developing country settings. 
 
 
The tuberculosis model  
 
Irregular adherence to treatment will almost inevitably lead to the development of viral resistance. 
Antiretroviral treatment is thus very much like treatment for tuberculosis. It has therefore been 
suggested that ARVs might be delivered via the vertically implemented tuberculosis model, in 
which a health care worker directly observes treatment-taking behavior. This approach needs to be 
evaluated in how well it can be applied to HIV treatment programs, as there are a number of 
significant differences between HIV treatment and TB treatment. For instance, TB treatment 
consists of a fixed combination of drugs, and this combination does not need to be adapted to suit 
individual patients. Even more important, TB treatment is taken for a limited period of time, 
typically for six months in short-course treatment regimens, while antiretroviral treatment is 
lifelong. The latter requires a different relationship between health care providers and clients and 
over a much longer period of time. There is certainly merit in some form of observed treatment, 
but, given that a very large number of people might eventually be on antiretroviral treatment, there 
is also a need to explore involving non–health provider observers, such as family members, 
treatment buddies,1 or members of the community, as long as they are chosen or identified with the 
explicit consent of clients and not by the health system alone. 
 
 
                                                
Public and private models  
 
Many people living with HIV/AIDS will seek care through the private sector, which in many 
developing countries is still the only source of antiretroviral therapy. This suggests the need for 
public-private partnerships to build on the strengths of each sector and also to address a number of 
1“Buddy” is a term used to describe a family member, friend, or acquaintance who provides one-on-one 
support to a person living with HIV/AIDS. 
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concerns. One concern is the quality and consistency of care. Additional training of both public and 
private physicians in antiretroviral treatment is needed. Another issue is the very real possibility 
that clients on treatment will move from provider to provider according to their ability to pay and 
the availability of drugs. This carries the risk of changes in treatment regimen and thus of drug 
resistance. In addition, patients with limited financial resources may put pressure on providers to 
avoid expensive antiretroviral combinations and expensive laboratory tests. This underscores the 
importance of collaboration, and, when indicated, referral, between the public and private sector. 
 
Within the public sector, questions arise about which type of health care worker should provide 
antiretroviral therapy, and at what level of the health care system this treatment should be provided. 
In other words, what is the lowest level at which treatment decisions can be made while still 




Antiretroviral treatment programs: Access and equity  
 
The health care delivery system, whether private or public, plays a key role in providing 
antiretroviral therapy. Many research questions about these systems were identified at the meeting, 
some of which are more biomedical but many of which are amenable to an operations research 
approach.  While there is agreement that antiretroviral treatment is only one component of a 
comprehensive care program, it is not clear what the key components of such a program are and 
what the appropriate mix of treatment and care is at different levels of the system.     
 
Managers of antiretroviral treatment programs need to make decisions about the number and types 
of antiretroviral drugs that need to be available, and they need to establish guidelines and treatment 
protocols. A sustainable and continuous supply of drugs needs to be guaranteed, but the program 
needs to be flexible enough to adapt to new developments.   
 
Decisions also need to be made about the eligibility of individuals to receive treatment—in other 
words, what are the criteria a person needs to meet to begin receiving antiretroviral therapy? This 
in turn raises the issue of equity in access to treatment, or who will have access to ARVs. One of 
the criteria currently used in Uganda, for instance, is the client’s ability to cover the cost of the 
drugs. While such an approach contributes to the sustainability of the program, it also raises a 
number of concerns. Current treatment costs, even if subsidized, make treatment unaffordable to 
many, and may result in the serious risk of treatment interruptions for those who can afford 
treatment only intermittently. This, obviously, is not a problem in countries where ARVs are made 
available free of charge through the public sector, although these subsidies come at considerable 
cost to the government. In Thailand, for instance, 70 percent of the government AIDS budget is 
allocated to treatment and care, which includes laboratory support, screening, capacity building, 
treatment for OIs, and ARVs. Even in countries where treatment is free of charge, clients 
sometimes incur considerable direct and indirect costs, such as transportation and loss of income. 
 
Antiretroviral treatment programs could benefit greatly from involving people living with 
HIV/AIDS, to assist in planning for service delivery as caregivers and as educators to reduce 
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stigma and discrimination, and to educate the public, clients, and health care workers.  Different 





Antiretroviral therapy is a rapidly evolving field, with new drugs and new drug combinations 
becoming available continually. While storage requirements have become simpler and treatment 
regimens have become less complex, further simplification of treatment regimens might make 
large-scale treatment programs easier to implement and more feasible. Further research and 
development are also needed to reduce the side effects and toxicity of ARVs. The effects of 
structured treatment interruptions on quality of life and on viral suppression are currently being 
explored. Structured treatment interruption might provide a cost-effective approach to maximizing 
availability of and access to antiretroviral treatment, while minimizing the impact of drug toxicity 
and side effects on individual patients. Cost savings associated with treatment interruptions might, 
however, be offset by the need for frequent viral load and CD4 counts to monitor patients. 
 
Resistance to antiretroviral drugs develops rapidly in patients on mono-therapy and more slowly in 
patients on dual or triple therapy. However, even patients on triple therapy develop resistance, and 
mechanisms need to be put in place to monitor the response of patients to treatment. Viral strains 
that are resistant to one or more classes of antiretroviral drugs are especially likely to develop 
rapidly when adherence to treatment regimens is poor. The presence of resistant strains in a country 
requires that a larger selection of ARVs be provided, which in turn complicates individual patient 
management, increases the risk of adverse drug interactions, and increases the demands on the 





The health care needs of people living with HIV/AIDS can be seen as a continuum, both in terms 
of the ever-changing needs as people infected with HIV progress toward AIDS and, in many cases, 
death, and in terms of the relationships between individuals and their direct environment and the 
wider community. Figure 3 illustrates the continuum of care as it relates to HIV infection. A 
comprehensive HIV/AIDS care program must address the full continuum, which usually requires 
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Note: Many behaviors and care and support activities are relevant across the whole continuum. 
 
 
Health-seeking behavior is a complex issue that is influenced not only by the availability of 
services or treatment, but also by the perceived benefit of such services and by their accessibility 
and affordability. For example, experience in the United States has shown that migrant workers are 
often not aware of what services are available to them, have little confidence in public sector 
services, or may lack the means to access such services. Women in many developing countries 
have very limited access to available services. Service providers need to understand their clients 
and their needs and tailor services accordingly. Community-based organizations can play an 
important role in providing information and education and in working with service providers to 
increase the coverage and use of services. Community education efforts might help create a more 
supportive and conducive environment for care and treatment programs, and might lead to more 
realistic expectations for such programs. Involving people living with HIV/AIDS in care programs 
can also greatly contribute to a better understanding of the needs of PLHA and might reduce stigma 
and discrimination within the community, thus reducing an important barrier to care.  
 
A first step in the continuum of care for HIV/AIDS is voluntary counseling and testing, as depicted 
in Figure 4. VCT services in many countries in the developing world are currently not able to meet 
the demand for such services. Yet as ARVs become available, it is likely that demand for VCT will 
increase rapidly. Alternative ways to offer VCT, including making them available outside the 
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traditional health care system, should be considered and evaluated. Moreover, the impact of testing 
and counseling on the psychosocial health of individuals needs to be explored.  
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The care continuum for HIV/AIDS, as shown in Figure 4, is characterized by frequent interactions 
between clients and health care providers, and provider behavior and attitudes are important in 
determining the acceptability, use, and success of treatment programs. It is important that program 
managers in treatment programs develop a good understanding of staff attitudes and behaviors and 
of staff motivation and fears. Staff training and support activities need to address a lack of 
understanding of the nature of HIV infection and AIDS, fear of contagion, and judgmental and 
pejorative staff attitudes. In addition, given the strong emotional issues around HIV/AIDS, 
psychosocial support services for health care staff should be made available. Finally, the care 
continuum requires good collaboration and referrals between all of the various service providers, 
institutions, and programs involved.  
 
People with HIV who seek care early on are unlikely to be eligible for or to need antiretroviral 
therapy. They will often, however, require psychosocial care and support to deal with the 
knowledge of being infected with HIV and with issues of disclosure, further prevention of 
infection, and possible stigma and discrimination. Professional sources of psychosocial support are 
likely to be limited and it is suggested that lay sources be explored. An important source of 
psychosocial support could be the family and the community, provided that issues of disclosure, 
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associated stigma and discrimination, and possible disclosure-related violence are addressed. 
Psychosocial support is also an important component of home-based, palliative, and end-of-life 
care. 
 
The provision of antiretroviral therapy raises a large number of behavioral issues, many of which 
are poorly understood and therefore in need of further research. Clients and communities need to 
understand that not everyone who is HIV-positive needs immediate treatment; but that once 
treatment is initiated it needs to be continued lifelong. Moreover, arbitrary treatment interruptions 
may lead to viral resistance, which may jeopardize future treatment. However, structured treatment 
interruptions may contribute to long-term adherence, by temporarily removing the pressure of daily 
treatment adherence and by alleviating side effects of ARVs. Thus, adherence to treatment 
regimens is a major concern. In Brazil, for instance, intensive public and private sector efforts are 
made to promote adherence, but these have not been evaluated well enough. It was noted, however, 
that adherence tends to be poorer for people of lower socioeconomic status.  
 
Little is known about what determines good adherence, and this should be an urgent focus of 
operations research. Lessons could be learned from directly observed treatment (DOT) programs 
for tuberculosis, for which treatment defaulting has been linked to an inadequate understanding by 
patients of the disease and the treatment program. The effect on treatment adherence of an 
approach that combines early testing and the preparation by the health care provider and the client 
of a long-term management plan should be explored. Different approaches to ensuring treatment 
adherence should be evaluated, such as ways to help clients disclose and involve others in 
adherence, the use of treatment buddies, group approaches to treatment, use of treatment managers 
(professional or lay), and home and community support.  
 
An area of special concern is the effect of antiretroviral therapy on protective and preventive 
behaviors. It has been speculated that the availability of antiretroviral therapy has changed the 
perception of HIV/AIDS from a universally fatal condition to a manageable chronic disease. 
Consequently, there might be less incentive to adopt and maintain preventive behaviors (Scheer et 
al. 2001; Stolte 2001 et al.). However, this association has been made on the basis of cross-
sectional studies that may not necessarily capture other factors that contribute to changes in risk 
behavior. Longitudinal studies are needed to further explore this issue. It was pointed out by 
meeting participants that there might be substantial misunderstanding and incorrect interpretation 
of statements about the outcome of antiretroviral treatment. For instance, statements about an 
undetectable or low viral load as a consequence of antiretroviral treatment should not be 
interpreted as meaning that people on treatment are cured or that they cannot infect others. 
Clarifying these kinds of issues requires a clear communication strategy, not only for patients but 
also for communities at large.  
 
 
Stigma, Discrimination, and Ethical Issues  
 
Successful HIV/AIDS programs, whether they focus on prevention or on care and support, demand 
careful attention to human rights issues, especially the rights of people living with HIV/AIDS. 
Some of these rights include the right to know one’s HIV status, the right to disclose one’s HIV 
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status, the right to confidentiality, the right to refuse participation in clinical trials, and the right to 
be treated with dignity and respect. These rights are severely compromised by stigma and 
discrimination, which still prevail in many parts of the world. For example, fear of stigma and 
discrimination will likely limit the number of people seeking VCT and thus treatment in some 
situations, while in others actual discrimination by health care providers reduces access to care and 
treatment for people living with HIV/AIDS. The impact of involving PLHA in prevention, care, 
and treatment programs on human rights issues needs to be further evaluated. 
 
The availability of ARVs may lead to a decrease in stigma and discrimination, as seems to have 
happened in parts of the industrialized world, or it may increase stigma and discrimination. 
Community involvement, the involvement of PLHA, and a good general understanding by the 
population of the potential benefits and the limitations of HIV/AIDS treatment and care might help 
reduce stigma and discrimination. On the other hand, limited availability of treatment in 
combination with increased disclosure by those seeking treatment or those on treatment might have 
the opposite effect.  
 
Instruments have been developed in some places to measure stigma and discrimination, but more 
work needs to be done in this area. Using such indicators would allow for an assessment of the 
degree to which human rights are respected in service delivery programs and the effect of such 
programs on stigma and discrimination. 
 
Countries must ensure that the conditions necessary for the health of individuals and populations 
are met. This responsibility raises questions about equity of access to information, means of 
prevention, and treatment. At the same time, resources are limited and public health programs are 
often forced to ration and prioritize. While universal access to cost-effective drugs for palliative 
care, treatment of opportunistic infections, antiretroviral drugs, and behavior change programs is 
the ultimate goal, choices have to be made in the meantime that will almost always lead to 
inequities in access. Broad-based advocacy for access to treatment, as happened in Brazil and 
Thailand, may increase the demand for and the availability of treatment. In other parts of the world, 
community mobilization could also prove to be an important step in increasing access to treatment.  
 
It is important that programs define indicators to identify inequities in access to treatment and to 
monitor progress toward greater equity. In the meantime, many questions remain about who has or 
will have access to treatment and what criteria should be applied to determine eligibility for ARV 
treatment. The application of clinical criteria seems fairly uncontroversial, but criteria regarding 
ability to pay, membership within a particular community, expectations concerning adherence, or 
geographic location are all likely to result in considerable inequity. While diagnostic studies might 
document current practices, operations research is urgently needed to support program managers in 
making sound, ethical decisions to determine access and selection criteria. Such research should 
also focus on a possible role of communities in deciding on and developing eligibility criteria. 
 
Choices concerning the range of ARVs available in a country also raise ethical questions. What are 
the implications of introducing a cheaper, but not necessarily optimal, combination of ARVs? For 
instance, highly active triple antiretroviral therapy might offer the highest success rates, but the 
cost might also preclude wider coverage of the program. Dual therapy with somewhat cheaper 
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drugs might be less effective, but could be offered to a much larger proportion of the eligible 
population. 
  
A number of ethical issues also arise concerning research, especially concerning clinical trials. 
Local ethical standards should be applied, but one unanswered question relates to the obligation of 
researchers after the end of a clinical intervention trial. Should the researchers provide lifelong 
antiretroviral treatment to study participants? Is there an obligation to extend such treatment to 






The community is an essential element in the life of individuals, providing context, cultural 
identity, and a network for care and support. Yet, with HIV/AIDS, lack of understanding, fear, and 
stigma and discrimination often mean that such support is lacking and that people living with 
HIV/AIDS are isolated. Community involvement is thus an important facet of HIV/AIDS 
programs, to reduce stigma and discrimination and to increase the potential for community care and 
support. In addition, involving NGOs and community-based organizations (CBOs) in program 
planning and implementation will probably help in formulating more appropriate and more 
sustainable programs. 
  
In terms of a community’s understanding of HIV/AIDS, a first step is to provide accurate 
information. Beliefs that either antiretroviral drugs or traditional treatments are curative need to be 
dispelled, while helping people understand that a range of care and treatment options other than 
only antiretroviral drugs is available. Training needs to be provided to NGOs to develop their 
capacity to deal with the various aspects of treatment programs, and to develop partnerships 
between organizations or institutions providing care, including antiretroviral treatment, and local 
NGOs and CBOs. Issues that can be addressed through such partnerships include disclosure, stigma 
and discrimination, community care and support, and resource mobilization. The community is also 
an essential partner in terms of articulating its needs with regard to a range of other health issues. 
Communities without established NGOs or CBOs offer a special challenge for community 
involvement.  
 
NGOs can play an important role in providing and supporting home-based and palliative care. 
Much can be done in palliative care that would improve the quality of life at relatively little cost. 
NGOs can also play an important role in helping individuals make decisions about allocating 
resources for HIV/AIDS and in planning for the future, including ways to care for orphans. 
 
Many NGOs and CBOs working in HIV/AIDS will attract people living with HIV/AIDS as 
volunteers or collaborators, although fear of stigma may prevent full disclosure. PLHA have, 
however, a unique role to play in promoting appropriate care and support, in providing insights into 




 It is essential that community people and community agencies are an integral part 
because they are not going to leave and they have the passion. (R. Cameron Wolf, HRSA) 
 
Community outreach is an important component of HIV care programs, to improve community 
understanding, increase health care–seeking behavior, reduce stigma and discrimination, and 
provide community- and home-based care and support. However, community outreach programs 
have not been evaluated, and questions remain about the potential and outcomes of home-based 
care programs, especially concerning training and psychosocial support needs of family health 
caregivers.  One particular group of individuals that could possibly be more involved in care and 
support are traditional healers. Their involvement fits well with an identified need to tap into the 
spiritual and broad cultural beliefs of the community.   
 
 
Cost and Cost Recovery 
 
Many see the cost of antiretroviral drugs as the limiting factor in making therapy widely available. 
For instance, cost was identified as a major impediment in scaling up in the UNAIDS pilot 
programs in Uganda, Chile, Côte d’Ivoire, and Vietnam. Most patients did not have enough 
resources to pay for the drugs, and this sometimes led to treatment interruptions. Moreover, as new 
drugs become available and as countries move from single or dual therapy to triple therapy, the 
cost is likely to increase even more.  
 
While a discussion of the cost of treatment is thus inextricably linked to the broader issue of access 
to treatment, many unanswered questions need to be investigated. An important question 
concerning any intervention is whether it is affordable, replicable in a larger geographic area, cost 
effective, and sustainable over time. In other words, is the intervention worth the investment of 
scarce resources? 
 
In terms of affordability and sustainability, one should balance the cost of treatment against the 
individual and societal savings that might accrue from treatment. It is also necessary to consider 
who pays for treatment (government, individuals, insurance agencies, NGOs) against who benefits 
and how many people benefit. For instance, who is willing and able to contribute to treatment 
costs? While a patient on treatment might use household savings to pay for treatment, being on 
treatment might also guarantee continued income to the household. 
 
In terms of providers, there is not enough experience with providing antiretroviral therapy to know 
what the direct and indirect costs are for service providers, and what the health care system will 
save in terms of future care costs. Little is also known about the short-term and long-term costs and 
savings to society. The larger the savings to society (the external benefits of treatment of 
individuals that accrue to the society), the stronger the argument for subsidizing antiretroviral 
treatment. Related to this issue is the question of the potential for community mobilization of 
resources. Different approaches to funding and resource mobilization, including insurance plans 
and risk pooling, need to be explored and evaluated. 
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As was pointed out earlier, there is a moral imperative to provide the best possible treatment to 
people who are ill with HIV/AIDS. The scarcity of resources, however, means that treatment 
programs will be in competition with other programs and that even within treatment programs, 
choices will have to be made.  Some of these choices are discussed under the Health System and 
Service Delivery section. Cost-effectiveness analyses could assist in making such choices, but 
many questions still remain about measuring cost-effectiveness of HIV/AIDS treatment programs. 
One such question is, what is the objective of the program? For instance, measuring outcomes in 
terms of reduced mortality or of disability-adjusted life years2 gained focuses on direct individual 
benefits but does not capture external outcomes. Measuring effectiveness requires a clear, 
unambiguous definition of outcomes at multiple levels: individual, family, community, and society.  
 
Given the resource constraints under which many countries are operating, a case could also be 
made to evaluate and compare the cost-effectiveness and cost benefits of antiretroviral treatment 
programs against the cost-effectiveness and cost benefits of other public health programs, such as 





The success of the antiretroviral therapy program in Brazil in providing treatment to substantial 
numbers of PLHA has been attributed to high levels of political support and the adoption of 
countrywide policies. A federal law passed in 1996 guarantees that ARVs will be provided for any 
person who needs them. An important factor in generating this political commitment has been the 
presence and activities of vocal and well-organized NGOs and political activists. Similarly, the 
success of the Thailand antiretroviral treatment program can be ascribed to the political will and the 
commitment to allocate a substantial proportion of the available resources to care and treatment of 
PLHA. In all fairness, it should be noted that in both Brazil and Thailand the resource base is much 
larger and the prevalence of HIV/AIDS is much lower than in many other developing countries, 
especially those in Sub-Saharan Africa. Even so, in Brazil a policy has been adopted to allocate 
considerable resources to the manufacture and importation of generic versions of patent-protected 
drugs to meet the country’s needs. 
 
But even in resource-constrained settings, governments can do much to create an environment that 
is conducive to effective prevention as well as appropriate care and support. Legislation against 
discrimination against those with HIV/AIDS and active promotion of their human rights will 
facilitate disclosure and help to strengthen services that respect and provide care for PLHA. 
Legislation and policies are needed to ensure the availability of condoms and other barrier 
methods, youth-friendly services, interventions to prevent transmission through drug injections to 
treat opportunistic infections, and, eventually, antiretroviral drugs. Research is needed to better 
understand and evaluate approaches to generating appropriate policy support for prevention, care, 
and support. 
 
                                                
2 Disability-adjusted life years (DALYs) provide a measure of the burden of disease, taking into account both 





To implement a successful, sustainable HIV/AIDS care and support program, a number of 
programmatic decisions need to be made. Further operations research is needed to inform such 
decisions, but some programs will certainly be implemented in the absence of research results. 
Among the many programmatic issues that have been identified as important are discussed below. 
 
HIV/AIDS programs need to balance prevention and care, and care programs need to take into 
account the needs of people living with HIV/AIDS along a continuum. This continuum ranges from 
testing, counseling, and psychosocial support to treatment of opportunistic infections, prevention of 
mother-to-child transmission, treatment with ARVs, and, finally, palliative and end-of-life care. 
The resources available and the epidemiological situation will influence the appropriate mix of 
activities along this continuum, but even a modest treatment program will require an expansion of 
VCT programs for HIV-positive individuals so that they are identified.  
 
For an antiretroviral therapy program to be successful, important decisions have to be made 
concerning the types and combinations of drugs that are made available, the criteria used to select 
PLHA to receive antiretroviral treatment, and the treatment delivery program that needs to be 
developed and implemented. Care should be taken to ensure equitable access to treatment, although 
it is unlikely that true equity will be achieved early on in treatment programs. Innovative 
approaches to promote treatment adherence need to be tested, such as the joint (client and provider) 
development of a treatment plan, the use of a treatment manager (health professional or lay 
person), or the use of a treatment buddy system. Communities and PLHA should be actively 
involved in the planning as well as implementation stages of the program, and the effect of such 
involvement should be evaluated. 
 
In addition, program managers need to develop and implement training programs for health care 
providers in the public and private sector, paying attention not only to clinical skills and 
knowledge, but also to attitudes and motivation. 
 
One of the biggest challenges, however, of an HIV/AIDS treatment program is to scale up in an 
equitable and sustainable manner. Lessons can be learned from experiences with the scaling up of 
programs to prevent MTCT. 
 
22  




Providing antiretroviral therapy as a component of comprehensive HIV/AIDS care is rapidly 
becoming a reality in some countries and is becoming a distinct possibility in many other 
developing countries. Many questions remain, however, about the most effective, equitable, cost-
effective, and, above all, balanced implementation of such programs. Biomedical research will 
yield new and better drugs that are less toxic and easier to take. Clinical research will continue to 
improve and adapt drug combinations, taking into account viral resistance and side effects. 
However, considerable operations research is urgently needed to identify, analyze, and disseminate 
best experiences with treatment programs in different resource and epidemiological situations. A 
list of high-priority operations research questions is provided below, as formulated by the 
international experts participating in the Horizons Access to Treatment meeting. Although many of 
these research questions can be addressed in the context of ongoing or newly established treatment 
programs, there are advantages to identifying specific learning sites for ARV programs in which 
different models of VCT and treatment provision can be tested and evaluated. 
 
 




1. What is the most appropriate mix of care interventions in settings with considerable 
resource constraints? What is the most effective way to identify the different needs of 
different groups (for example, by age, sex, or geographical location) for care? 
 
2. What are the factors and characteristics that make for successful service delivery 
programs? What are the benefits of models with centralized versus decentralized 
providers? 
 
3. What is needed to improve the motivation and confidence of health care workers? 
Specifically, what is needed in terms of training, salaries, support, and backstopping? What 
training is needed for health care workers in the private sector? 
 
4. Where and at what level of the health care system can antiretroviral therapy be provided? 
What are the minimum requirements for infrastructure, laboratory support, combination of 
drugs, staff, and community involvement that are needed to maintain a basic standard of 
quality of care? 
 
5. What are the quality of care and the use of different service delivery models? How can 
quality of service be ensured?  
 
6. How can the potential of private providers best be maximized? What are models for 




Behavioral questions including adherence 
 
1. Which factors contribute to adherence to treatment, for both OIs and ARV therapy?  
 
2. What is the impact of comprehensive care and prevention programs on adherence? 
 
3. How does the use of non-medical providers affect maintenance of treatment regimens? 
What is the effect on adherence of using a buddy system compared to treatment managers 
or to involvement of family and/or community? 
 
4. Can ARVs be introduced without reducing protective behaviors? Will the introduction of 
ARVs increase high-risk behaviors? 
 
 
Equity and accessibility 
 
1. How equitable is the provision of treatment (for both OIs and ARVs) and what are the 
criteria being used to select recipients of ART? How are these criteria developed, applied, 
and enforced? 
 
2. What are the specific needs of different groups in a society for care and treatment, and who 
can best meet these needs?  
 
3. From an epidemiological and a public health benefits standpoint, are there some high-risk 





1. What processes or approaches help ensure the meaningful involvement of communities in 
designing and implementing HIV/AIDS care and treatment programs?  What is the effect 
of involving communities in designing and implementing treatment and care programs? 
What is the role of communities in care provision? 
 
2. What are the community’s preferences for accessing treatment, in terms of sources of care 
and types of care? 
 
3. What is the effect of involving PLHA on the coverage, use, and success of treatment 
programs? 
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Cost 
 
1. What are the most feasible and effective models for resource mobilization, including risk 
pooling, insurance, and community resource mobilization?  
 
2. What is the range of costs and cost-effectiveness for different care options, including 
antiretroviral therapy and treatment for opportunistic infections? What is the range of costs 
and cost-effectiveness for different treatment options?   
 
3. How much will care and support for people living with HIV/AIDS cost? What is the 
benchmark for cost-effectiveness? How big are the externalities3 associated with care and 
support, and how can these be maximized? 
 
4. What proportion of therapy can user fees cover? What is the willingness and ability of 
clients to pay for different treatment options? 
 
5. What is the implication of user fees on the financial wellbeing of families? 
 
 
Stigma, discrimination, and ethical issues 
 
1. Which training or other approaches are likely to reduce reducing stigma and discrimination 
among health care providers? 
 
2. What effect will scaling up VCT and care and support programs have on stigma and 
discrimination? What is the effect of the availability of treatment on stigma and 
discrimination?  
 
3. What type of care, support, and treatment interventions will reduce stigma and 
discrimination in the community and in the health care sector? 
 
4. What is the scope for providing antiretroviral therapy for prevention purposes? What are 
the ethical and patient management implications of such therapy? 
 
 
                                                
3 Externalities are the benefits that go beyond the individual benefits, such as, for instance, the benefit to 
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Access to Treatment for HIV/AIDS:  
Directions for Operations Research Consultative Meeting 
12 and 13 June 2001 
 
Washington Plaza Hotel, Jefferson Room 





Assist the Horizons Program in refining and prioritizing operations research questions that address 
access to treatment for HIV/AIDS, and to identify potential research partners. The meeting will 
focus on the following key questions: 
1. What are the operational issues encountered in providing HIV/AIDS treatment in different 
country settings?  
2. What are the most important operational challenges and testable solutions in providing 
access to treatment?   
3. How do these challenges and solutions differ by region and subpopulation? 
4. What are some of the important research design and measurement issues that need to be 




Tuesday, June 12 
 
9:00 – 10:00 Introduction of participants and objectives  
Andrew Fisher, Horizons 
 
10:00 – 10:40 Overview And Discussion of Access to Treatment Services  
Eric van Praag, FHI/IMPACT 
 
10:40 – 11:00 Coffee Break 
 
11:00 – 11:30 USAID's Access to Treatment Priorities and Programs  
David Stanton, USAID 
 
11:30 - 12:00 Reaching the Hard to Reach in the United States: Treatment Priorities and 
Program Approaches  
Barbara Aranda-Naranjo and R. Cameron Wolf, HRSA  
 
12:00 - 12:30 Discussion 
Moderator: Simon Baker, Horizons 
 
12:30 - 1:30  Lunch 
34  
Access to Treatment 
 
Balance of Day Critical reflection on country experiences with access to treatment 
for HIV/AIDS: What does a country need to do to increase access to 
treatment? What are the challenges? What are the potential solutions? 
What operations research has been done within countries on access 
issues? What was learned? What research needs to be done? The format 
is 15 minutes for each presentation followed by 5 minutes for clarifying 
questions. After all of the country presentations, a general discussion will 
follow.  
  
1:30 - 1:50 UNAIDS Four Country Pilot Provision of ARVs  
Jos Perriens, UNAIDS 
 
1:50 - 2:10  Thailand  
Somsong Rugpao and Anupung Chitwarakorn, Department of 
Communicable Disease Control, Ministry of Health, Thailand 
  
2:10 - 2:30 Uganda  
Peter Mugyenyi, Joint Clinical Research Centre 
 
2:30 - 3:00  Discussion 
   Moderator: Ann McCauley, Horizons 
 
3:00 - 3:20  Break 
 
3:20 - 3:40   Brazil  
Francisco Inácio Bastos, Oswaldo Cruz Foundation 
 
3:40 - 4:00  South Africa  
   Mark Lurie, Medical Research Council, South Africa 
 
4:00 - 4:20  India  
A.K. Ganesh, YRG Care 
 
4:20 - 5:00 Discussion 
 Moderator: Naomi Rutenberg, Horizons 
 
5:00 – 6:30  Reception 
 
Wednesday, June 13 
 
9:00 - 9:30 Synopsis of Challenges and Solutions from Previous Day 
Johannes van Dam, Horizons 
 
Balance of Day Discussion of Five Key Topics: For each topic, identify operations research 
questions, design and measurement challenges, problem areas, and 




9:30  - 10:20 Service Delivery, Illustrative Questions: What are the supplies, 
equipment, and logistics issues that need to be addressed? What are the 
provider competence issues? How can we create PLHA-friendly treatment 
centers? What are the implications for voluntary testing and counseling of 
increased access to treatment? Is there an opportunity to change MTCT 
programs, moving from single therapy to triple therapy?   
Presenter: Sam Kalibala, Horizons 
Moderator: Helena Walkowiak, MSH 
 
10:20 - 10:40 Coffee Break 
 
10:40 - 11:30 Behavioral Issues, Illustrative Questions: How can a high level of 
patient adherence to drug regimens be maintained? Is a DOT program 
feasible? Are there dangers of an increase in unsafe sex practices as ARV 
patients perceive themselves to not be at risk?   
Presenter: Julie Pulerwitz, Horizons 
Moderator: Mary Bassett, University of Zimbabwe 
 
11:30 - 12:20 Community Involvement, Illustrative Issues: What is the role of 
communities and NGOs in access to treatment? How can they foster a 
high level of patient adherence and facilitate information dissemination, 
particularly among low-literate populations?    
Presenter: Eka Esu-Williams, Horizons 
Moderator: Stephen Kinoti, SARA Project, AED  
 
12:20- 1:30 Lunch 
 
1:30 – 2:20 Human Rights, Illustrative Questions: What are the human rights, 
equity, ethical, and gender issues concerning who will have access to 
treatment? Can treatment programs reduce stigma and discrimination? 
How can treatment programs accurately track patients without stigmatizing 
them?   
 Presenter: Chris Castle, Horizons 
 Moderator: Ron MacInnis, USAID 
 
2:20 – 3:00 Cost, Illustrative Questions: What are the operational cost issues that 
need to be examined? Is fee for services a viable approach?    
Presenter: Rick Homan, FHI 
 Moderator: Mike Sweat, Johns Hopkins University 
 
3:00 – 3:20 Break 
 
3:20 – 4:10 Setting Operations Research Priorities for Horizons 
Moderator: Johannes van Dam, Horizons 
 
4:10 - 4:20 Wrap-up   
Andrew Fisher, Horizons 
  
36  
Horizons is a global operations research 
program designed to: 
	 Identify and test potential strategies to 
	 improve HIV/AIDS prevention, care, and 
	 support programs and service delivery.
	 Disseminate best practices and utilize 
	 findings with a view toward scaling up
	 successful interventions.
For more information, please contact:
Horizons Program, Communications Unit
4301 Connecticut Avenue, NW Suite 280





Horizons is implemented by the 
Population Council in collaboration with
· International Center for Research on 
  Women (ICRW)
· International HIV/AIDS Alliance
· Program for Appropriate Technology in 
  Health (PATH)
· Tulane University
· University of Alabama at Birmingham
· Family Health International (FHI)
· Johns Hopkins University
Y E A R S
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